CompoAtlas

Senokot

Originaltext auf Französisch.

In Kanada zugelassenes natürliches Gesundheitsprodukt

Falls dieses Produkt in Frankreich verkauft würde

Nach den von uns angewandten Vorschriften wurde kein Punkt festgestellt.

Eine Tagesmenge wird nur bei ausdrücklicher oraler Dosierung für Erwachsene berechnet, die pro Tag und in einer zur Produktform passenden festen Einheit angegeben ist. Mehrdeutige Einheiten, Flüssigkeiten, Pulver und pädiatrische Dosen werden nicht hochgerechnet. Eine nicht berechnete Menge wird nicht mit Dosisgrenzwerten verglichen. Diese Analyse stellt weder eine Verkaufszulassung in Frankreich noch eine Sicherheits- oder Wirksamkeitsbewertung dar.

Zusammensetzung

Arzneilicher Inhaltsstoff und QuelleJe Dosiseinheit laut QuelleTäglich höchstens, Erwachsene
Standardized Sennosides

Quelle : Dried pods of Cassia acutifolia Delile

Stärke : 8,6 mg Standardized Sennosides

8,6 mgNicht berechnet

Nicht arzneiliche Inhaltsstoffe

Starch, Corn, Stéarate de magnésium, Microcrystalline cellulose, Hydroxypropylcellulose, Oxyde de fer (Fe2O3), Eau purifiée, Glycérine, Hypromellose, Dioxyde de titane

In Kanada empfohlene Dosen

BevölkerungsgruppeAlterMenge pro EinnahmeHäufigkeit
AdultesNon préciséeminimum : 2 Comprimé ; maximum : 4 Compriméminimum : 1 Tous les jours ; maximum : 2 Tous les jours
Enfantsminimum : 6 ans ; maximum : 12 ansminimum : 1 Comprimé ; maximum : 2 Compriméminimum : 1 Tous les jours ; maximum : 2 Tous les jours

In Kanada zugelassene Verwendungen

For relief of functional constipation (occasional). Promotes bowel movement by direct action on the large intestine. The natural source senna in all Senokot products provides comfortable, overnight relief from occasional constipation.

Originaltext auf Englisch.

Eine in Kanada zugelassene Verwendung ist keine in der Europäischen Union zugelassene gesundheitsbezogene Angabe. Beachten Sie das Register gesundheitsbezogener Angaben.

Warnhinweise in Kanada

Cautions and Warnings : Reduce dose or discontinue use if you experience abdominal pain, griping (cramps or spasms) and/or diarrhea. Do not use in the presence of fecal impaction and undiagnosed, acute or persistant gastrointestinal complaints (e.g., abdominal pain, nausea, fever or vomiting) as these symptoms can be signs of a potential or existing intestinal blockage or ileus. Consult a healthcare practitioner if symptoms persist or worsen. Laxatives should not be taken within two hours of another medicine because the desired effect of the other medicine may be reduced. If rectal bleeding or failure to have a bowel movement (after use occurs, discontinue therapy and consult a physician, as this may indicate a serious condition. If there has been a sudden change in your bowel movements that persists over a 2 week period, consult a physician before use. Consult a physician prior to use if you are taking thiazide diuretics, corticosteroids, licorice root or other medications or health products which may aggravate electrolyte imbalance. Consult a physician prior to use if you have a kidney disorder or are taking cardiac medications such as cardiac glycosides or antiarrhythmic medications. Long-term use of stimulant laxatives should be avoided as it may lead to impaired function of the intestine, dependence on laxatives, dehydration and electrolyte imbalance (including hypokalemia). Concomitant therapy with other drugs or herbal substances known to induce hypokalemia (e.g. diuretics, adrenocorticosteroids and liquorice root) may enhance the electrolyte imbalance. Prolonged excessive use or misuse of these products may also result in the development of atonic colon. Fertility, Pregnancy and Lactation: Consult a physician before use. There are no reports of undesirable or damaging effects during pregnancy or on the fetus associated with senna preparations when used in accordance with the recommended dosage schedule. However, as a consequence of experimental data concerning a genotoxic risk of several anthranoids (e.g. emodin and aloe-emodin), use is not recommended during pregnancy. Small amounts of active metabolites (rhein) are excreted in breast milk. A laxative effect in breast fed babies has not been reported. However, use during breastfeeding is not recommended as there are insufficient data on the excretion of metabolites in breast milk. Symptoms and Treatment of Overdosage: The major symptoms of overdose abuse of any stimulant laxative, including those containing senna, are gripping pain and severe diarrhea, leading to excessive water loss (dehydration) and possible electrolyte imbalance (hypokalemia). Treatment should be supportive with generous amounts of fluid. Electrolytes, especially potassium, should be monitored. This is especially important in the elderly. In case of overdose: Call a Regional Poison Control Centre and/or your physician and/or your local emergency number immediately, or go to your local hospital emergency, even if you do not notice any signs or symptoms.

Originaltext auf Englisch.

Contra-Indications : Do not use if you are hypersensitive to the active substance (sennosides) or to any ingredient in the formulation; have an acute surgical abdomen; abnormal constrictions of the gastrointestinal tract; potential or existing intestinal blockage and stenosis; ileus; atonic bowel; appendicitis; inflammatory bowel disease such as Crohn¿s disease or ulcerative colitis; abdominal pain of unknown origin; undiagnosed rectal bleeding and severe dehydration with depleted water or electrolytes.

Originaltext auf Englisch.

Known Adverse Reactions : Due to the presence of chrysophanic acid in natural senna, Senokot® laxatives may cause discolouration of breast milk, urine, or feces depending on the acidity (yellow-brown discolouration) or alkalinity (red-violet discolouration) of the substance. There is no pathological significance to this discolouration. Urine discolouration (chromaturia), if present, may interfere with the interpretation of laboratory tests. Reversible pigmentation of the colon, i.e. melanosis coli, may also result from prolonged use of senna containing preparations. The adverse reactions listed below are classified according to their incidence (common or uncommon). Common adverse reactions have an incidence of = 1% and include the following: abdominal pain. Uncommon adverse reactions have an incidence of < 1% and include the following: anaphylactic reaction, anaphylactoid reaction, breast milk discolouration, chromaturia, feces discoloured, nausea, rash erythematous, rash maculo-papular, perianal irritation, rectal hemorrhage, urticaria and vomiting. Adverse reactions of unknown frequency include the following: diarrhea, hypersensitivity and pruritus.

Originaltext auf Englisch.

Produktdaten

Andere Namen
Senokot For Women
Inhaber
iNova Pharmaceuticals (Australia) Pty Limited
NPN oder DIN-HM
00026158
Status
Aktive Lizenz
Lizenzdatum
23. November 2009
Überarbeitungsdatum
7. Januar 2025
Form
Comprimé
Verabreichungsweg
Orale
Art des Antrags
Non traditionnelle

Quelle

Amtlicher Health-Canada-Eintrag, Zulassung 00026158

Licensed Natural Health Products Database (LNHPD), Health Canada: zugelassene Produkte, Inhaltsstoffe, Dosierungen, Verwendungen und Warnhinweise, abgerufen am 27. Oktober 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Originaltext auf Englisch.

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

Originaltext auf Französisch.

Die unter demselben Namen in Europa verkaufte Rezeptur kann abweichen. Diese Angaben ersetzen keinen ärztlichen oder pharmazeutischen Rat.

Liste in der amtlichen Überarbeitung vom (Register: Licensed Natural Health Products Database (LNHPD), Health Canada: zugelassene Produkte, Inhaltsstoffe, Dosierungen, Verwendungen und Warnhinweise).

Das Produkt hat sich geändert? Fotografieren Sie die Verpackung.

Ist eine Angabe zu diesem Produkt falsch oder veraltet, ob Sie Leser oder Marke sind? Schreiben Sie an contact@compoatlas.com: Jede Korrektur wird im Korrekturprotokoll veröffentlicht.

Eingabetaste zum Analysieren, Umschalt+Eingabetaste für eine neue Zeile